Message From the Editor-in-Chief
Message From the Editor-in-Chief
2014 Volume 78 Issue 12 Pages 2805-2806
Details
2014 Volume 78 Issue 12 Pages 2805-2806
Dear Colleagues,
On behalf of the Circulation Journal, I would like to let you know the top 42 papers most frequently cited in the 2013 issues of the Circulation Journal. The number in the parenthesis denotes the number of citations in Circulation Journal in the year of 2013.
1. (14) Kumagai K. Catheter ablation of atrial fibrillation: State of the Art. Circ J 2011; 75: 2305–2311. (Review)
2. (13) Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–992.
3. (11) Saito I. Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan. Circ J 2012; 76: 1066–1073. (Review)
4. (10) Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiog 2005; 18: 1440–1463. (Review)
5. (9) Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845–1853.
(9) Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501–2555.
(9) Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J 2011; 75: 1801–1810. (Review)
(9) Berne P, Brugada J. Brugada Syndrome 2012. Circ J 2012; 76: 1563–1571. (Review)
9. (8) Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001; 285: 2370–2375.
(8) Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344–2351.
(8) Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961–972.
(8) Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251–259.
(8) Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: Report of the second consensus conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: 659–670. (Review)
(8) Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The pathology of neoatherosclerosis in human coronary implants: Bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314–1322.
(8) Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J 2011; 75: 2739–2748. (Review)
(8) Momomura S, Tsutsui H, Sugawara Y, Ito M, Mitsuhashi T, Fukamizu S, et al. Clinical efficacy of cardiac resynchronization therapy with an implantable defibrillator in a Japanese population: Results of the MIRACLE-ICD outcome measured in Japanese indication (MOMIJI) study. Circ J 2012; 76: 1911–1919.
17. (7) Cleland JGF, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539–1549.
(7) Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter: Defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225–237.
(7) Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193–202. (Review)
(7) Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008; 117: 2608–2616.
(7) Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435–2441.
(7) Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy: The magnitude of the problem and the issues. Circ J 2011; 75: 521–527. (Review)
(7) Kinugawa K. How to treat stage D heart failure?: When to implant left ventricular assist devices in the era of continuous flow pumps? Circ J 2011; 75: 2038–2045. (Review)
(7) Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, et al. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure: Comparison between preserved and reduced ejection fraction heart failure. Circ J 2011; 75: 2605–2613.
25. (6) Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877–883.
(6) Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. New Engl J Med 2003; 349: 1315–1323.
(6) Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825–1833.
(6) Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93: 841–842.
(6) McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med 1971; 285: 1441–1446.
(6) Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000; 102: 1788–1794.
(6) Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
(6) Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539–2550. (Review)
(6) Tonino PAL, De Bruyne B, Pijls NHJ, Siebert U, Ikeno F, van’t Veer M, et al; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009; 360: 213–224.
(6) Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure: Abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953–1959.
(6) Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations. Circulation 2003; 107: 714–720.
(6) Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010; 74: 213–220. (Review)
(6) De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve: Guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012; 367: 991–1001.
(6) Ago T, Kuroda J, Kamouchi M, Sadoshima J, Kitazono T. Pathophysiological roles of NADPH oxidase/nox family proteins in the vascular system: Review and perspective. Circ J 2011; 75: 1791–1800. (Review)
(6) Otsuka H, Arimura T, Abe T, Kawai H, Aizawa Y, Kubo T, et al. Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. Circ J 2012; 76: 453–461.
(6) Kim YH. Catheter ablation of longstanding persistent atrial fibrillation: Are we on the right path? Circ J 2012; 76: 1299–1306. (Review)
(6) Kubo T, Tanaka A, Kitabata H, Ino Y, Tanimoto T, Akasaka T. Application of optical coherence tomography in percutaneous coronary intervention. Circ J 2012; 76: 2076–2083. (Review)
(6) Aizawa Y, Sakata Y, Mano T, Takeda Y, Ohtani T, Tamaki S, et al. Transition from asymptomatic diastolic dysfunction to heart failure with preserved ejection fraction: Roles of systolic function and ventricular distensibility. Circ J 2011; 75: 596–602.
The Editorial Team looks forward to receiving manuscripts with high scientific impact from all over the world.
(Released online October 23, 2014)
